This figure, taken from the American College for Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis, provides a suggested pathway for the ongoing fracture risk assessment for patients who remain on treatment with glucocorticoids in the long term.
Link to paper:
https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.42646
Reference:
Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., Lane, N. E., Ma, N. S., Magrey, M., McAlindon, T., Robinson, A. B., Saha, S., Womack, C., Abdulhadi, B., Charles, J. F., Cheah, J. T. L., … Uhl, S. (2023). 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & rheumatology (Hoboken, N.J.), 75(12), 2088–2102. https://doi.org/10.1002/art.42646
